Breast Cancer

Data from the PANKU-Breast02 trial may support iza-bren as a new standard of care in this TNBC population.

For patients with early breast cancer receiving chemotherapy, the use of a dexamethasone mouthwash did not significantly reduce the incidence of oral mucositis.

Final analysis of KEYNOTE-522 confirms pembrolizumab plus chemotherapy improves event-free and overall survival in high-risk early-stage TNBC.

Sacituzumab govitecan plus pembrolizumab maintained PFS improvements vs chemotherapy plus pembrolizumab in first-line metastatic TNBC.

Results from the phase 3 lidERA Breast Cancer trial demonstrated a 35% reduction in the risk of invasive disease or death with giredestrant in this breast cancer population.

The assay may identify a group comprising approximately two-thirds of patients who do not have a meaningful chance of benefit from adjuvant chemotherapy.

Paolo Tarantino, MD, PhD, discussed how clinical aggressiveness, toxicity, and progression patterns guide the sequencing of ADCs in breast cancer care.

Patients with breast cancer and macrometastases who omitted axillary lymph node dissection experienced noninferior survival compared with those who didn’t.

Community-clinic data shows real-world EFS and pCR closely match KEYNOTE-522, strengthening confidence in real-world endpoints for eTNBC care.

Gedatolisib combinations significantly extend progression-free survival after CDK4/6 inhibitor failure in HR+/HER2– breast cancer, with manageable adverse effects and stable quality of life.

The FDA extends camizestrant review. Plus, promising Bria-IMT survival data and a ctDNA blood test that spots breast cancer recurrence 4 years early.

Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.

Sac-TMT demonstrated a significant improvement in PFS vs chemotherapy as first-line treatment for unresectable locally recurrent or metastatic TNBC.